Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Scientists use drinkometer to reveal how Weight-Loss drugs alter eating

NCT ID NCT07457424

Knowledge-focused Sponsor: University College Dublin Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study directly measures how GLP-1 medications (like Ozempic) change the way people eat. Researchers use a special device to track every sip of sugary and fatty drinks in 140 adults with obesity. The goal is to understand exactly how these drugs reduce calorie intake, not just through questionnaires but by observing real eating patterns.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 140 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2022

Expected to finish

Jan 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

People with BM\>30 who are started GLP-1 for treating obesity and people with BMI\>30 without using internal weight loss measures and no history of GLP-1 analog. Also, healthy people with BMI\>18.5 and \<24.9 are involved in the study.

Ages

18 to 75 years

Sex

Female participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18 to 75 * Treatment Group: BMI \> 30 kg/m2 and clinically indicated for GLP-1 RA's treatment. * Controls with obesity (BMI ≥ 30 kg/m2) with no history of GLP-1 RA's treatment. * Healthy normal weight controls (BMI \< 25 kg/m2) with no history of using GLP-1 RAs * Independently mobile * Capacity to consent to participate Exclusion Criteria: * Pre-treatment factors impairing the ability to consume meal such as Significant dysphagia * Gastric outlet obstruction * Systemic or gastrointestinal condition which may affect food intake or preference * Pregnancy or lactation (At the beginning of each study visit, a urine pregnancy test will be performed for all female participants). * Active and significant psychiatric illness including substance misuse * Significant cognitive or communication issues * Medications with documented effects on food intake or food preference * History of significant food allergy and certain dietary restrictions (except for lactose intolerance)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Metabolic disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Feeding Behavior metabolic disease Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Metabolic disease Obesity & overweight

Contacts and locations

Locations

  • Clinical Research Centre

    Dublin, Dublin, Dublin 4, Ireland

More trials for these conditions

Other studies related to the condition(s) this trial covers.